Total votes: 3

QRxPharma Ltd. is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. The Company’s lead products comprise a patented combination of existing drugs, with a well-defined path to regulatory approval and sales. QRxPharma’s lead drug compound, MoxDuo IR (Q8003IR), began Phase III clinical trials in November 2007. The Company’s preclinical and clinical pipeline includes other technologies in the fields of neurodegenerative disease and venomics.

Lead Product:
An 25 August 2009 ASX release re their lead product MoxDuo™ IR Demonstrated Fewer Side Effects than Percocet® Pain relieving effects of MoxDuo™ IR are doserelated with a better safety profile than Percocet® in patients with postoperative pain following total knee replacement.

MoxDuo™ IR is the first patented analgesic product in the world that consists of two opioid drugs (a fixed ratio of morphine and oxycodone). While many analgesic combination drugs exist that contain opioids with mild pain drugs such as aspirin, ibuprofen or acetaminophen, combination products such as Percocet®, which contains an opioid (oxycodone) combined with acetaminophen (like Tylenol®) have been the subject of recent FDA scrutiny due to their potential for causing significant adverse effects on liver and gastrointestinal function.

To date, more than 400 patients in six clinical trials have received MoxDuo™ IR for different forms of post‐surgical pain (bunionectomy and total knee replacement) and the drug is in Phase III trials.

Cash on Hand:
$17.8M at 30th June 2009 (provierd a runway until 2011 with current business plan)
$21.6M was then raised at the end of 2009.

Some Key people:
Chairman Peter Farrell (Founder and Chairman of Resmed)
CEO John Holaday

Possible Upcoming Events:
 - Initial strategic partnership
 - FY11-FY12 raise and extra $60M for support of products